Anavex Life Sciences Corp.
AVXL · FY2025 · Fiscal year ended Sep 30, 2025 · 10-K filed Nov 2025
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $0K | $0K | |
| Operating income | −$51.4M | −$52.9M | +2.8% |
| Net income | −$46.4M | −$43.0M | −7.9% |
Latest quarter: Q3 FY2026
Form 10-Q · Three months ended Jun 30, 2026 · filed Aug 28, 2026
| $ | Q3 FY2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $0K | $0K | |
| Operating income | $6.70M | −$14.5M | |
| Net income | $7.80M | −$13.2M |
Q3 FY2026 dashboardQ3 FY2026 infographic
Questions
- What was Anavex Life Sciences's revenue in FY2025?
- $0K in FY2025 (Fiscal year ended Sep 30, 2025), no comparable figure vs $0K a year earlier, per its 10-K filed Nov 2025.
- Was Anavex Life Sciences profitable in FY2025?
- No: net income was −$46.4M and operating income −$51.4M in FY2025.
- What was Anavex Life Sciences's revenue in Q3 FY2026?
- $0K (n/a vs a year earlier), per its Form 10-Q filed Aug 28, 2026.